Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MKK900 RSV Vaccine in Healthy Women
NCT07492706Phase 1Not yet recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MKK900 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by MAXVAX Biotechnology. Primary endpoints: Frequency of solicited local and systemic adverse events at 7 days, Frequency of unsolicited adverse events at 30 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
MKK900
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07492706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492706.